Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004;2004(3):CD003775.
doi: 10.1002/14651858.CD003775.pub2.

Hepatitis B vaccination for patients with chronic renal failure

R J Schroth, C A Hitchon, J Uhanova, A Noreddin, S P Taback, M E K Moffatt, J M Zacharias

Hepatitis B vaccination for patients with chronic renal failure

R J Schroth et al. Cochrane Database Syst Rev. 2004.

Abstract

Background: Chronic renal failure patients are at particular risk of hepatitis B virus infection. Early studies have demonstrated that renal failure patients benefit from vaccination; however, not all studies have consistently shown benefit.

Objectives: To determine the beneficial and harmful effects of hepatitis B vaccine and of a reinforced vaccination series in chronic renal failure patients.

Search strategy: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Renal Group Controlled Trials Register, The Cochrane Controlled Trials Register on The Cochrane Library (Issue 1, 2002),PubMed/MEDLINE (1966 to July 2003), EMBASE (1985 to November 2003), Current Clinical Practice Guidelines (Canadian Immunization Guide and Vaccine Preventable Diseases Surveillance Manual), and Science Citation Index as well as journals, published abstracts, and reference lists of articles.

Selection criteria: Randomised clinical trials comparing plasma vaccine with placebo, recombinant vaccine with placebo, recombinant vaccine with plasma vaccine, and a reinforced vaccination series (ie, more than three inoculations) with three inoculations of vaccine in chronic renal failure patients.

Data collection and analysis: Primary outcome measures included incidence of patients developing hepatitis B virus antibodies and infections while secondary outcomes included adverse events, liver-related morbidity, and mortality. Random effects models were used and reported relative risks and 95% confidence intervals (RR and 95% CI).

Main results: We included seven randomised clinical trials. None of them had high quality. Plasma vaccine was significantly more effective than placebo in achieving hepatitis B antibodies (RR 23.0, 95% CI 14.39 to 36.76, 3 trials). We found no statistically significant difference between plasma vaccine or placebo regarding hepatitis B virus infections (RR 0.50, 95% CI 0.20 to 1.24). We found no statistically significant differences between recombinant vaccine and plasma vaccine in achieving hepatitis B antibodies (RR 0.65, 95% CI 0.28 to 1.53, 2 trials). Heterogeneity was significant and appeared to be attributable to the dose of vaccine. Two trials examined a reinforced recombinant vaccine strategy, which was not statistically more effective than three inoculations of recombinant vaccine regarding development of hepatitis B antibodies (RR 1.36, 95% CI 0.85 to 2.16).

Reviewers' conclusions: Plasma derived vaccines are more effective than placebo in achieving hepatitis B antibodies, while no statistically significant difference was found between recombinant and plasma vaccines. No statistically significant difference of effectiveness was observed between a reinforced vaccination series versus routine vaccinations of three inoculations of recombinant vaccine.

PubMed Disclaimer

Conflict of interest statement

None known.

Update of

  • doi: 10.1002/14651858.CD003775

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Crosnier 1981 {published data only}
    1. Crosnier J. Hepatitis B in haemodialysis: vaccination against HBs antigen. Proceedings of the European Dialysis and Transplantation Association. European Dialysis and Transplant Association. 1981; Vol. 18:231‐40. - PubMed
    1. Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, et al. Randomised placebo‐controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet 1981;1(8224):797‐800. - PubMed
    1. Degos F, Courouce AM, Vitviski L, Lacour B, Crosnier J. Incidence of hepatitis during a placebo controlled study of vaccine against hepatitis B virus. Liver 1982;3 Pt 2(2):317.
Desmyter 1983 {published data only}
    1. Desmyter J, Colaert J, Groote G, Reynders M, Reerink‐Brongers EE, Leli PN, et al. Efficacy of heat‐inactivated hepatitis B vaccine in haemodialysis patients and staff. Double‐blind placebo‐controlled trial. Lancet 1983;2(8363):1323‐8. - PubMed
El‐Reshaid 1994 {published data only}
    1. El‐Reshaid K, Al‐Mufti S, Johny KV, Sugathan TN. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine 1994;12(3):223‐38. - PubMed
Jilg 1986a {published data only}
    1. Jilg W, Schmidt M, Weinel B, Kuttler T, Brass H, Bommer J, et al. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. Journal of Hepatology 1986;3(2):190‐5. - PubMed
Jilg 1986b {published data only}
    1. Jilg W, Schmidt M, Weinel B, Kuttler T, Brass H, Bommer J, et al. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. Journal of Hepatology 1986;3(2):190‐5. - PubMed
Jungers 1994a {published data only}
    1. Jungers P, Chauveau P, Courouce AM, Abbassi A, Devillier P, Marie FN, et al. [Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity]. La Presse Medicale 1994;23(6):277‐80. - PubMed
    1. Jungers P, Chauveau P, Courouce AM, Devillier P, Excler JL, Bailleux F, et al. Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients. The Journal of Infectious Diseases 1994;169(2):399‐402. - PubMed
Seaworth 1988a {published data only}
    1. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccine in patients with chronic renal failure before dialysis. The Journal of Infectious Diseases 1988;157(2):332‐7. - PubMed
Seaworth 1988b {published data only}
    1. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccine in patients with chronic renal failure before dialysis. The Journal of infectious diseases 1988;157(2):332‐7. - PubMed
Stevens 1984 {published data only}
    1. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. The New England Journal of Medicine 1984;311(8):496‐501. - PubMed

References to studies excluded from this review

Andre 1987 {published data only}
    1. Andre FE, Safary A. Summary of clinical findings on Engerix‐B, a genetically engineered yeast derived hepatitis B vaccine. Postgraduate Medical Journal 1987;63 Suppl2:169‐77. - PubMed
Chang 1996 {published data only}
    1. Chang PC, Schrander‐van der Meer AM, Dorp WT, Leer E. Intracutaneous versus intramuscular hepatitis B vaccination in primary non‐responding haemodialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association ‐ Eurpoean Renal Association 1996;11(1):191‐3. - PubMed
Charest 2000 {published data only}
    1. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. American journal of kidney diseases: the official journal of the National Kidney Foundation 2000;36(5):976‐82. - PubMed
Jungers 1994b {published data only}
    1. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo‐controlled trial of recombinant interleukin‐2 in chronic uraemic patients who are non‐responders to hepatitis B vaccine. Lancet 1994;344(8926):856‐7. - PubMed
Propst 1998 {published data only}
    1. Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 1998;32(6):1041‐5. - PubMed
Vincent 1998 {published data only}
    1. Vincent L, John GT, Abraham P, Jacob CK. An intradermal vaccine protocol against hepatitis B in a haemodialysis population. The National Medical Journal of India 1998;11(1):48. - PubMed
Vlassopoulos 1999 {published data only}
    1. Vlassopoulos DA, Arvanitis DK, Lilis DS, Louizou KI, Hadjiconstantinou VE. Lower long‐term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients. The International Journal of Artificial Organs 1999;22(11):739‐43. - PubMed

Additional references

Alexander 1998
    1. Alexander D, Peacock E, Curry G, Jacob G. Immunizing the ESRD patient population: providers face challenges. Nephrology News & Issues 1998;12(10):42‐4;45‐6;66. - PubMed
CDC 2001
    1. Center for Disease Control. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report: Recommendations and Reports/Centers for Disease Control. Vol. 50 (RR‐5), Altanta, Georgia: CDC, 2001:1‐43. - PubMed
Chatenoud 1986
    1. Chatenoud L, Dugas B, Beaurain G, Touam M, Drueke T, Vasquez A, et al. Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. Proceedings of the National Academy of Sciences of the United States of America 1986;83(19):7457‐61. [MEDLINE: ] - PMC - PubMed
Chatenoud 1990
    1. Chatenoud L, Herbelin A, Beaurain G, Descamps‐Latscha B. Immune deficiency of the uremic patient. Advances in nephrology from the Necker Hospital 1990;19:259‐74. [MEDLINE: ] - PubMed
Clarke 2001
    1. Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.4 [updated October 2001]. In: The Cochrane Library, Issue 4. 2001. Oxfrod: Update Software. Updated quarterly.
CONSORT Statement
    1. Moher D, Schulz KF, Altman DG for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. www.consort‐statement.org (accessed 21 November 2002). - PubMed
Dukes 1993
    1. Dukes CS, Street AC, Starling JF, Hamilton JD. Hepatitis B vaccination and booster in predialysis patients: a 4‐year analysis. Vaccine 1993;11(12):1229‐32. - PubMed
Engels 2000
    1. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J. Heterogeneity and statistical significance in meta‐analysis: an empirical study of 125 meta‐analyses. Statistics in Medicine 2000;19(13):1707‐28. - PubMed
Fabrizi 2000
    1. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. American Journal of Nephrology 2000;20(1):1‐11. - PubMed
Fabrizi 2001
    1. Fabrizi F, Martin P, Lunghi G, Ponticelli C. Novel evidence on hepatitis B virus infection in dialysis. The International Journal of Artificial Organs 2001;24(1):8‐16. - PubMed
Feuerhake 1984
    1. Feuerhake A, Muller R, Lauchart W, Pichlmayr R, Schmidt FW. HBV ‐ vaccination in recipients of kidney allografts. Vaccine 1984;2(4):255‐6. [MEDLINE: ] - PubMed
Fivush 1998
    1. Fivush BA, Neu AM. Immunization guidelines for pediatric renal disease. Seminars in Nephrology 1998;18(3):256‐63. - PubMed
Geerlings 1991
    1. Geerlings W, Tufveson G, Brunner FP, Ehrich JH, Fassbinder W, Landais P, et al. Combined report on regular dialysis and transplantation in Europe, XXI, 1990. Nephrology, Dialysis, Tranpslantation: Official Publication of the European Dialysis and Transplant Association ‐ European Renal Association 1991;6 Suppl4:5‐29. - PubMed
Girndt 2002
    1. Girndt M, Kohler H. Hepatitis B virus infection in hemodialysis patients. Seminars in Nephrology 2002;22(4):340‐50. [PMID 12118399] - PubMed
Huang 1997
    1. Huang CC. Hepatitis in patients with end‐stage renal disease. Journal of Gastroenterology and Hepatology 1997;12(9‐10):S236‐41. - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. - PubMed
Jefferson 2000
    1. Jefferson T, Demicheli V, Deeks J, MacMillan A, Sassi F, Pratt M. Vaccines for preventing hepatitis B in health‐care workers. Cochrane Library 2000, Issue 1. - PubMed
Johnson 1992
    1. Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clinical Pharmacokinetics 1992;22(6):434‐46. - PubMed
Jüni 2001
    1. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. British Medical Journal 2001;323(7303):42‐6. - PMC - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed
Lefebure 1993
    1. Lefebure AF. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine 1993;11(4):397‐9. - PubMed
MacKellar 2001
    1. MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, Ford W, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. American Journal of Public Health 2001;91(6):965‐71. - PMC - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad A, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analysis. Lancet 1998;352(9128):609‐13. - PubMed
Moher 1999
    1. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUORUM statement. Lancet 1999;354(9193):1896‐900. - PubMed
Petrosillo 1993
    1. Petrosillo N, Puro V, Ippolito G. Prevalence of human immunodeficiency virus, hepatitis B virus and hepatitis C virus among dialysis patients. The Italian Multicentric Study on Nosocomial and Occupational Risk of Blood‐Borne Infections in Dialysis. Nephron 1993;64(4):636‐9. [MEDLINE: ] - PubMed
Popper 1990
    1. Popper H, Schaffner F. Progress in liver diseases. Vol. 9, Toronto: W.B. Saunders Company, 1990.
Rangel 2000
    1. Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Seminars in Dialysis 2000;13(2):101‐7. - PubMed
Revillard 1979
    1. Revillard JP. Immunologic alterations in chronic renal insufficiency. Advances in Nephrology from the Necker Hospital 1979;8:365‐82. [MEDLINE: ] - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Specter 1999
    1. Specter SC. Hepatitis B vaccines. In: Specter SC editor(s). Viral Hepatitis: Diagnosis, Therapy, and Prevention. Totowa, NJ: Humana Press, 1999:377‐91. [ISBN 0‐89603‐424‐0]
Tokars 1998
    1. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO Journal (American Society for Artificial Internal Organs: 1992) 1998;44(1):98‐107. [MEDLINE: ] - PubMed
Tokars 2000
    1. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis‐associated diseases in the United States, 1997. Seminars in Dialysis 2000;13(2):75‐85. - PubMed
Torres 1996
    1. Torres JR. Hepatitis B and hepatitis delta virus infection in South America. Gut 1996;38 Suppl 2:S48‐55. - PMC - PubMed
Walker 1999
    1. Walker A. Meta‐style and expert review. Lancet 1999;354(9193):1834‐5. - PubMed
Zannolli 1997
    1. Zannolli R, Morgese G. Hepatitis B vaccine: current issues. The Annals of Pharmacotherapy 1997;31(9):1059‐67. - PubMed

Publication types

MeSH terms

Substances